Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GB 004

Next Previous
Search
Drug Profile

GB 004

Alternative Names: AKB-4924; GB-004

Latest Information Update: 02 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Procter & Gamble
  • Developer Gossamer Bio; Whitehawk Therapeutics
  • Class Anti-inflammatories; Antiulcers; Piperazines; Pyridones; Small molecules
  • Mechanism of Action Hypoxia inducible factor 1 modulators; Prolyl hydroxylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Inflammatory bowel diseases; Ulcerative colitis

Most Recent Events

  • 18 Mar 2025 Aadi Bioscience is now called Whitehawk Therapeutics
  • 24 Jul 2022 Gossamer terminates license agreement with Aadi Bioscience as its phase II SHIFT-UC trial did not meet the primary or secondary endpoints
  • 29 Jun 2022 Gossamer Bio terminates the phase II SHIFT-UC trial in Ulcerative colitis (In the elderly, In adults) in USA, Georgia, South Korea, Moldova, Poland, Russia, Romania, Serbia and Ukraine (PO) due to lack of treatment benefit (NCT04556383) (EudraCT2020-002306-12)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top